Date published: 2026-2-10

1-800-457-3801

SCBT Portrait Logo
Seach Input

cGKI alpha Inhibitors

Santa Cruz Biotechnology now offers a broad range of cGKI alpha Inhibitors for use in various applications. cGKI alpha, or cyclic GMP-dependent protein kinase I alpha, is a key enzyme involved in numerous cellular processes, including smooth muscle contraction, synaptic plasticity, and the regulation of gene expression. cGKI alpha Inhibitors are essential tools in scientific research, providing a means to precisely modulate this kinase's activity and study its role in cellular signaling pathways. Researchers utilize these inhibitors to investigate the effects of cGKI alpha suppression on intracellular signaling cascades, particularly in relation to how cGMP signaling pathways are controlled and how these pathways influence cellular responses. By inhibiting cGKI alpha, scientists can explore the downstream effects on its substrates and associated molecular interactions, leading to a better understanding of how this kinase regulates physiological processes such as vasodilation, neurotransmitter release, and cytoskeletal dynamics. The use of cGKI alpha Inhibitors is pivotal in research areas such as molecular biology, neuroscience, and biochemistry, where explaining the function of protein kinases is crucial for advancing knowledge of cellular mechanisms and signaling networks. These inhibitors enable researchers to dissect the specific contributions of cGKI alpha to various cellular functions, offering insights into the complex regulation of kinase activity and its broader implications in cellular homeostasis. View detailed information on our available cGKI alpha Inhibitors by clicking on the product name.

Items 11 to 20 of 22 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

SR 48692

146362-70-1sc-363290
sc-363290A
sc-363290B
sc-363290C
sc-363290D
5 mg
25 mg
100 mg
500 mg
1 g
$159.00
$605.00
$2374.00
$10710.00
$21410.00
2
(0)

This analog increases cGMP production by activating particulate guanylyl cyclase, leading to enhanced PKG1 activity.

Genistein

446-72-0sc-3515
sc-3515A
sc-3515B
sc-3515C
sc-3515D
sc-3515E
sc-3515F
100 mg
500 mg
1 g
5 g
10 g
25 g
100 g
$45.00
$164.00
$200.00
$402.00
$575.00
$981.00
$2031.00
46
(1)

A tyrosine kinase inhibitor, modulates receptor tyrosine kinase signaling, potentially influencing cGKIα.

Dimethyloxaloylglycine (DMOG)

89464-63-1sc-200755
sc-200755A
sc-200755B
sc-200755C
10 mg
50 mg
100 mg
500 mg
$84.00
$301.00
$374.00
$779.00
25
(2)

An inhibitor of guanylyl cyclase, reducing cGMP production and thus PKG1 activity by decreasing its activator concentration.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

A p38 MAP kinase inhibitor, affects MAPK signaling, potentially impacting cGKIα.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

An ERK inhibitor, modulates MAPK/ERK pathways, potentially influencing cGKIα.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

A JNK inhibitor, affects JNK signaling, potentially influencing cGKIα.

PT 1

331002-70-1sc-361299
sc-361299A
10 mg
50 mg
$185.00
$781.00
1
(2)

A chemical compound that acts upstream to reduce cGMP levels, thereby indirectly inhibiting PKG1 activation.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

A PI3K inhibitor, modulates AKT signaling pathways, potentially impacting cGKIα.

Zaprinast (M&B 22948)

37762-06-4sc-201206
sc-201206A
25 mg
100 mg
$105.00
$250.00
8
(2)

Zaprinast inhibits PDE5 and possibly other cGMP-degrading phosphodiesterases, increasing cGMP levels and enhancing PKG1 activity.

Staurosporine

62996-74-1sc-3510
sc-3510A
sc-3510B
100 µg
1 mg
5 mg
$82.00
$153.00
$396.00
113
(4)

A broad-spectrum protein kinase inhibitor, affects multiple kinase pathways, potentially influencing cGKIα.